Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CEST
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at [email protected]

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
04:00p RESULTS OF AGIOS PHARMACEUTICALS INC : AGIO) Midstage Trial Released
06/25 CELGENE : Federal Contracts Awarded by Federal Agencies in Illinois (June 25)
06/24 CELGENE : $1.56 Million Federal Contract Awarded to Celgene
06/23 ALLIQUA BIOMEDICAL, INC. (NASDAQ : ALQA) Files An 8-K Unregistered Sales of Equi..
06/23 CELGENE : Award Notice - V797d-70166 Celgene Corporation
06/23 CELGENE : CONTRACT AWARD - 65-- V797d-70166 Celgene Corporation
06/22 CELGENE : Dragonfly Therapeutics Announces Strategic Collaboration with Celgene ..
06/22 CELGENE : Celebrated Photographer Martin Schoeller Shines a Light on People With..
06/22 CELGENE : Celebrated Photographer Martin Schoeller Shines a Light on People With..
06/20 Celgene wins the Adam Smith Award for Best Card Solution with Basware, Citi a..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/26 BIOTECH BOOM! : Overview And Company-By-Company Review
06/24 Biotech Forum Daily Digest - Biotech Soars! Spotlight On Novacure
06/22 CELGENE : I Don't Necessarily Understand The Science, But I Love The Numbers
06/22 Market Is Divided Between Growth And Value - Cramer's Mad Money (6/21/17)
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
Advertisement
Financials ($)
Sales 2017 13 201 M
EBIT 2017 7 400 M
Net income 2017 4 786 M
Debt 2017 1 927 M
Yield 2017 -
P/E ratio 2017 22,69
P/E ratio 2018 18,53
EV / Sales 2017 8,06x
EV / Sales 2018 6,71x
Capitalization 104 513 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 142 $
Spread / Average Target 6,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION15.64%104 873
AMGEN18.78%126 856
GILEAD SCIENCES-0.52%92 150
REGENERON PHARMACEUTIC..40.93%54 987
VERTEX PHARMACEUTICALS81.09%33 251
ACTELION23.36%30 469
More Results